These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 17096161)

  • 1. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
    Minderman H; Zhou Y; O'Loughlin KL; Baer MR
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):245-55. PubMed ID: 17096161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
    Horton TM; Gannavarapu A; Blaney SM; D'Argenio DZ; Plon SE; Berg SL
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):13-23. PubMed ID: 16292537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
    Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
    Lü S; Chen Z; Yang J; Chen L; Zhou H; Xu X; Li J; Han F; Wang J
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e123-31. PubMed ID: 19254348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the LRP (lung resistance-related protein) gene by short-term exposure of human leukemia cells to phorbol ester and cytarabine.
    Komarov PG; Shtil AA; Holian O; Tee L; Buckingham L; Mechetner EB; Roninson IB; Coon JS
    Oncol Res; 1998; 10(4):185-92. PubMed ID: 9778689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
    Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
    Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines.
    Lun M; Zhang PL; Siegelmann-Danieli N; Blasick TM; Brown RE
    Ann Clin Lab Sci; 2005; 35(1):15-24. PubMed ID: 15830705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
    Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
    Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    Yerlikaya A; Erin N
    Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
    Lü S; Yang J; Song X; Gong S; Zhou H; Guo L; Song N; Bao X; Chen P; Wang J
    J Pharmacol Exp Ther; 2008 Aug; 326(2):423-31. PubMed ID: 18502982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.